Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
June 24, 2019 07:30 ET
|
Minerva Neurosciences, Inc
Primary endpoint, defined as Latency to Persistent Sleep (LPS) at Night 1, showed improvement with a p-value ≤0.001 after treatment with 10 and 20 mg doses of seltorexantKey secondary endpoint,...
Minerva Neurosciences to Host Live Conference Call and Webcast With Key Opinion Leaders to Discuss Successful Insomnia Trial With Seltorexant
June 23, 2019 17:30 ET
|
Minerva Neurosciences, Inc
Call scheduled for 8:30 a.m. Eastern Time on June 24 to review results of successful Phase 2b trial showing achievement of primary and secondary endpoints with potential first-in-class specific...
Minerva Neurosciences to Present at Jefferies 2019 Global Healthcare Conference on June 4, 2019
May 29, 2019 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs
May 13, 2019 08:15 ET
|
Minerva Neurosciences, Inc
Potential first-in-class, oral specific orexin-2 inhibitor demonstrates statistically significant improvement in MADRS scores at 6 weeks compared to placebo Well tolerated, with adverse events similar...
Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates
May 06, 2019 07:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019
April 29, 2019 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates
March 12, 2019 07:30 ET
|
Minerva Neurosciences, Inc
Recruitment active in five late-stage trials with three compounds directed toward significant unmet medical needs Target indications include schizophrenia, major depressive disorder and insomnia...
Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates
May 03, 2018 07:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates
March 12, 2018 07:30 ET
|
Minerva Neurosciences, Inc
Four late-stage trials underway, targeting schizophrenia, major depressive disorder and insomnia disorder Planning for commercialization moves forward Management to host conference call today at...
Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018
March 05, 2018 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...